Insulin Glargine "All to Target" Trial
Information source: Sanofi
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus, Type 2
Intervention: Insulin Glulisine (Drug); Insulin Glargine (Drug); Premixed Insulin (Drug); Insulin Glulisine (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Sanofi Official(s) and/or principal investigator(s):
Medical Affairs, Study Director, Affiliation: Sanofi
Summary
The primary objectives were:
- To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra®
(Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of
patients achieving target glycemic control (as measured by hemoglobin A1c [HbA1c]
<7. 0%) at Week 60
- To demonstrate the noninferiority of Lantus plus addition of 1 mealtime Apidra
injection (Lantus/Apidra-1) versus twice-daily Premixed insulin based on the reduction
from Baseline to Week 60 in HbA1c
Clinical Details
Official title: All to Target Trial Lantus® (Insulin Glargine) With Stepwise Addition of APIDRA® (Insulin Glulisine) or Lantus With One Injection of Apidra vs a Twice-Daily Premixed Insulin Regimen (Novolog® Mix 70/30) in Adult Subjects With Type 2 Diabetes Failing Dual or Triple Therapy With Oral Agents: a 64-week, Multi-center, Randomized, Parallel, Open-label Clinical Study.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol Population Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)
Secondary outcome: Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30) Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 Without a Severe Hypoglycemic Event or a Symptomatic Hypoglycemic Event With an Self Monitoring Blood Glucose (SMBG) <50 mg/dl Adjusted Incidence Rate of Hypoglycemia Adjusted Hypoglycemic Event Rates (Event/Patient-year)
Eligibility
Minimum age: 30 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
- Male or female patients
- 30 to 80 years of age
- Body Mass Index <45 kg/m2
- With Type 2 diabetes mellitus for at least 2 years
- With an HbA1c level at screening of >7. 5% and >7. 0% at randomization
- On stable dual or triple oral therapy for at least 3 months
- Oral agents in 2 or 3 of the following classes: SU or repaglinide, biguanide, or TZD,
willing and able to perform self-monitoring of BG
- Females of child-bearing potentially were required to be willing and able to use
adequate contraception
Locations and Contacts
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Additional Information
Starting date: May 2006
Last updated: May 4, 2011
|
